Superworth

Rocket Pharmaceuticals price to book ratio RCKT

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
0.7×
10-year median
3.3×
Against its 10-year history
5th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 15.5×
Peer median
2.2×

Rocket Pharmaceuticals' price to book ratio is 0.7× as of Oct 23, 2026.

That is below its ten-year median of 3.3×, lower than on 95% of days in the last ten years.

Over that time it ranged from 0.4× in Jul 2017 to 15.5× in Mar 2018.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.7×0.6×2.0×
20251.2×0.7×3.5×
20243.2×3.2×5.6×
20235.0×2.7×5.0×
20224.0×1.3×4.6×
20212.9×2.9×14.7×
202012.5×2.3×13.6×
20195.2×2.2×5.2×
20184.0×1.6×15.5×
20171.4×0.4×1.5×
20161.9×1.5×2.7×
20152.6×2.3×9.3×

Against its peers

Companies in Drug Manufacturers - General nearest Rocket Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
RCKTRocket Pharmaceuticals0.7×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
Peer median2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Rocket Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.